Tissue Extraction Devices Retains IPinvestments Group to Commercialize its Intellectual Property Portfolio Related to Biopsy Devices.

INDIANAPOLIS & ATLANTA -- Tissue Extraction Devices, LLC, a privately held Indianapolis-based company focused on developing innovative medical devices, today announced that the company has advanced their strategic intellectual property initiative by retaining IPinvestments Group, an intellectual property business advisory firm, to market Tissue Extraction Device's medical device technology ("IP Portfolio"). The IP Portfolio consists of four (4) allowed and pending U.S. Patent applications and a pending interference action filed with the U.S. Patent and Trademark Office against U.S. Patent No. 6,758,824 (assigned to Suros Surgical Systems, Inc. which is now part of Hologic, Inc.).

The IP Portfolio provides numerous technologies that can be applied to a pneumatically controlled medical device. While the technologies can be applied to many devices, the improvements provided in the IP Portfolio would particularly benefit breast biopsy devices that are both on the market and in development. Among many other advantages, a medical device built in accordance with the IP Portfolio would be operable in an MRI environment.

"This IP Portfolio represents fundamental technologies crucial to medical devices, and will be of interest to any company involved in the medical device industry," stated Jeffrey Schwindt, president of Tissue Extraction Devices. "Our strategy is to maximize the value of our intellectual property by finding the right company to acquire and commercialize this technology, thus providing more effective screening and identification of cancer and other deadly ailments affecting our families and friends."

Tissue Extraction Devices believes that the IP Portfolio is foundational to the growing Breast Disease Diagnostic and Therapeutic Devices Market, among other market opportunities. According to a recently issued industry report by Life Science Intelligence, the U.S. market alone for devices used to diagnose and treat breast disease will grow from $1.2 billion in 2006 to $2.7 billion by 2012. Major companies that participate in this industry include, among others, Johnson & Johnson (Ethicon Endo-Surgery), Hologic (Suros Surgical Systems), C.R. Bard, Siemens, General Electric, Philips, Cytyc, SenoRx and SonoSite.

The first phase of our efforts will be focused on finding a partner for an outright acquisition of the portfolio. It is anticipated that this will be accomplished through a deliberate, strategic auction process over the next few months. In addition to selling the assets, Mr. Schwindt would consider partnering with a company to further develop and commercialize the technology.

Companies interested in receiving additional information regarding the opportunity may contact either Michael McLaughlin or Grant Moss of IPinvestments Group at 404-962-8740, or via email at [e-mail] or [e-mail].

About Tissue Extraction Devices, LLC

Tissue Extraction Devices, a privately held company based in Indianapolis, IN, is focused on developing innovative medical devices and related technology to meet today's most difficult medical challenges. Currently, the company has four (4) active U.S. patent applications, one of which has already been allowed by the U.S. Patent and Trademark Office. The president, Mr. Jeffrey Schwindt, is an accomplished inventor and also founded Air Systems Engineering, Inc. in 1993. Air Systems Engineering, also known as A.S.E., has long been a leading designer and builder of pneumatic and electric automation equipment.

About IPinvestments Group, LLC

IPinvestments Group is an intellectual property business advisory firm committed to extracting maximum value from intellectual property assets. Headquartered in Atlanta, Georgia, IPinvestments Group specializes in transaction and licensing services related to patented technologies and innovations. For more information, please visit www.ipinvestmentsgroup.com.